Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection.

IF 5.3 2区 医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL
Molecular Therapy Oncolytics Pub Date : 2023-09-01 eCollection Date: 2023-09-21 DOI:10.1016/j.omto.2023.08.014
Raquela J Thomas, Mee Y Bartee, Miriam Valenzuela-Cardenas, Eric Bartee
{"title":"Oncolytic myxoma virus is effective in murine models of triple negative breast cancer despite poor rates of infection.","authors":"Raquela J Thomas,&nbsp;Mee Y Bartee,&nbsp;Miriam Valenzuela-Cardenas,&nbsp;Eric Bartee","doi":"10.1016/j.omto.2023.08.014","DOIUrl":null,"url":null,"abstract":"<p><p>Oncolytic viruses are being heavily investigated as novel methods to treat cancers; however, predicting their therapeutic efficacy remains challenging. The most commonly used predictive tests involve determining the <i>in vitro</i> susceptibility of a tumor's malignant cells to infection with an oncolytic agent. Whether these tests are truly predictive of <i>in vivo</i> efficacy, however, remains unclear. Here we demonstrate that a recombinant, oncolytic myxoma virus shows efficacy in two murine models of triple negative breast cancer despite extremely low permissivity of these models to viral infection. These data demonstrate that <i>in vitro</i> infectivity studies are not an accurate surrogate for therapeutic efficacy and suggest that other tests need to be developed.</p>","PeriodicalId":18869,"journal":{"name":"Molecular Therapy Oncolytics","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/3e/main.PMC10507476.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy Oncolytics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omto.2023.08.014","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/21 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Oncolytic viruses are being heavily investigated as novel methods to treat cancers; however, predicting their therapeutic efficacy remains challenging. The most commonly used predictive tests involve determining the in vitro susceptibility of a tumor's malignant cells to infection with an oncolytic agent. Whether these tests are truly predictive of in vivo efficacy, however, remains unclear. Here we demonstrate that a recombinant, oncolytic myxoma virus shows efficacy in two murine models of triple negative breast cancer despite extremely low permissivity of these models to viral infection. These data demonstrate that in vitro infectivity studies are not an accurate surrogate for therapeutic efficacy and suggest that other tests need to be developed.

Abstract Image

Abstract Image

Abstract Image

溶癌性粘液瘤病毒在癌症三阴性小鼠模型中是有效的,尽管感染率很低。
溶瘤病毒作为治疗癌症的新方法正在被大量研究;然而,预测它们的治疗效果仍然具有挑战性。最常用的预测测试包括确定肿瘤恶性细胞对溶瘤剂感染的体外易感性。然而,这些测试是否真的能预测体内疗效,目前尚不清楚。在这里,我们证明了重组溶瘤粘液瘤病毒在两种三阴性乳腺癌症小鼠模型中显示出有效性,尽管这些模型对病毒感染的允许性极低。这些数据表明,体外感染性研究不是治疗效果的准确替代品,并表明需要开发其他测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Therapy Oncolytics
Molecular Therapy Oncolytics Medicine-Oncology
CiteScore
10.90
自引率
3.50%
发文量
152
审稿时长
6 weeks
期刊介绍: Molecular Therapy — Oncolytics is an international, online-only, open access journal focusing on the development and clinical testing of viral, cellular, and other biological therapies targeting cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信